Frontiers in reproductive health · 2026
Comparative outcomes of conventional follitropin delta 15 µg/day versus follitropin alfa 225 IU/day for ovarian stimulation: results from an exploratory post hoc analysis of Spanish participants from the ADAPT-1 randomized controlled trial.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
García Sánchez Marta, Bernabeu Andrea, Hernández Cesteros Ana, Blasco Gastón Laura, Ortega Ricondo Sofia, Castillón Gemma, Ferrando Serrano Marcos, Møgelmose Signe, Gravotta Enrica, Lobo Rita
Аннотация
RESEARCH QUESTION: Can follitropin delta be used in a conventional regimen (15 µg/day starting dose) without compromising efficacy and safety in patients seeking fertility treatment in Spain?
DESIGN: This was an exploratory post hoc analysis of the ADAPT-1 randomized controlled trial. Participants, 18-40 years, enrolled at specialist reproductive centers in Spain in this accessor-blinded, multicenter trial assessing efficacy and safety of conventional follitropin delta 15 μg/day and follitropin alfa 225 IU/day for ovarian stimulation. The primary endpoint was the number of oocytes retrieved. During the follow-up period, clinical pregnancies from the first fresh or frozen transfer within 3 months of the start of stimulation, and ovarian hyperstimulation syndrome (OHSS) rates were assessed. All cycles used a gonadotropin-releasing hormone (GnRH) antagonist protocol.
RESULTS: A total of 132 patients were randomized (10-AUG-2022 to 11-MAR-2024): follitropin delta group, n = 85; follitropin alfa group, n = 47. The adjusted mean number of oocytes retrieved was 10.6 and 11.0 for each group, respectively [difference: -0.3 (95% CI: -2.4; 1.7)]. Adjusted clinical pregnancy rates per started cycle were 34.8% and 32.0%, respectively [difference: 2.8% (95% CI: -14.3; 20.0)]. Adverse events were reported for 28.2% and 42.6% of participants, respectively, with the most common adverse events being headache [10.6% (n = 9) and 8.5% (n = 4)], pelvic discomfort [4.7% (n = 4) and 4.3% (n = 2)], dysmenorrhea [0% and 6.4% (n = 3)], and early OHSS [1.2% (n = 1) and 4.3% (n = 2)].
CONCLUSIONS: Our exploratory analysis shows that a higher starting dose of follitropin delta 15 µg/day in a conventional regimen can be successfully used in appropriately selected infertile patients, resulting in a good average oocyte yield without compromising first-transfer clinical pregnancy rates and while maintaining a low incidence of early OHSS.
DESIGN: This was an exploratory post hoc analysis of the ADAPT-1 randomized controlled trial. Participants, 18-40 years, enrolled at specialist reproductive centers in Spain in this accessor-blinded, multicenter trial assessing efficacy and safety of conventional follitropin delta 15 μg/day and follitropin alfa 225 IU/day for ovarian stimulation. The primary endpoint was the number of oocytes retrieved. During the follow-up period, clinical pregnancies from the first fresh or frozen transfer within 3 months of the start of stimulation, and ovarian hyperstimulation syndrome (OHSS) rates were assessed. All cycles used a gonadotropin-releasing hormone (GnRH) antagonist protocol.
RESULTS: A total of 132 patients were randomized (10-AUG-2022 to 11-MAR-2024): follitropin delta group, n = 85; follitropin alfa group, n = 47. The adjusted mean number of oocytes retrieved was 10.6 and 11.0 for each group, respectively [difference: -0.3 (95% CI: -2.4; 1.7)]. Adjusted clinical pregnancy rates per started cycle were 34.8% and 32.0%, respectively [difference: 2.8% (95% CI: -14.3; 20.0)]. Adverse events were reported for 28.2% and 42.6% of participants, respectively, with the most common adverse events being headache [10.6% (n = 9) and 8.5% (n = 4)], pelvic discomfort [4.7% (n = 4) and 4.3% (n = 2)], dysmenorrhea [0% and 6.4% (n = 3)], and early OHSS [1.2% (n = 1) and 4.3% (n = 2)].
CONCLUSIONS: Our exploratory analysis shows that a higher starting dose of follitropin delta 15 µg/day in a conventional regimen can be successfully used in appropriately selected infertile patients, resulting in a good average oocyte yield without compromising first-transfer clinical pregnancy rates and while maintaining a low incidence of early OHSS.